Purified anti-mouse Ly-6G/Ly-6C (Gr-1) Antibody

Product Details

Verified Reactivity

Mouse

Antibody Type

Monoclonal

Host Species

Rat

Immunogen

Raised against granulocytes of mouse origin

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Preparation

The antibody was purified by affinity chromatography.

Concentration

0.5 mg/ml

Storage & Handling

The Ly-6G/Ly-6C antibody solution should be stored undiluted between 2°C and 8°C.

Application

FC - Quality tested
IP, IHC, WB - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.06 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Clone RB6-8C5 binds with high affinity to mouse Ly-6G molecules and to a lower extent to Ly-6C¹⁹. Clone RB6-8C5 impairs the binding of anti-mouse Ly-6G clone 1A8¹⁹. However, clone RB6-8C5 is able to stain in the presence of anti-mouse Ly-6C clone HK1.4²⁰.

The RB6-8C5 antibody has been used to identify peripheral blood neutrophils and deplete granulocytes in vivo. Additional reported applications (for relevant formats of this clone) include: in vitro complement-mediated cytotoxicity², in vivo depletion^3-5,9, immunoprecipitation¹, immunohistochemical staining⁶ (including paraffin-embedded sections^9,16,33-35, acetone-fixed frozen sections¹¹ and zinc-fixed sections¹⁵), and Western blotting⁷. RB6-8C5 is not suitable for depletion of hepatic myeloid derived suppressor cells (MDSCs)²⁰.

Special Note: For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 108436).

Application References

1. Fleming TJ, et al. 1993. J. Immunol. 151:2399. (IP)
2. Brummer E, et al. 1984. J. Leukocyte Biol. 36:505. (CMCD)
3. Stoppacciaro A, et al. 1993. J. Exp. Med. 178:151. (Deplete)
4. Tumpey TM, et al. 1996. J. Virol. 70:898. (Deplete)
5. Czuprynski CJ, et al. 1994. J. Immunol. 152:1836. (Deplete)
6. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
7. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819. (WB)
8. Engwerda CR, et al. 2004. Am. J. Pathol. 165:2123.
9. Brown CR, et al. 2004. Infect. Immun. 72:4956. (Deplete, IHC)
10. Andoniou CE, et al. 2005. Nature Immunology 6:1011. (FC) PubMed
11. Li M, et al. 2006. P. Natl. Acad. Sci USA 103:11736. (IHC)
12. Dzhagalov I, et al. 2007. Blood 109:1620. (FC) PubMed
13. Fazilleau N, et al. 2007. Nature Immunol. 8:753. (FC) PubMed
14. Heuser M, et al. 2007. Blood 110:1639. (FC) PubMed
15. Wang T, et al. 2007. Infect. Immun. 75:1144. (IHC)
16. Bosio CM, et al. 2007. J. Immunol. 178:4538. (IHC)
17. Boehme SA, et al. 2009. Int. Immunol. 21:81. (IHC)
18. Piao Y, et al. 2012. Neuro Oncol. 14:1379. PubMed
19. Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
20. Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
21. Li J, et al. 2012. Arthritis Rheum. 64:1098. PubMed
22. Fan Q, et al. 2014. Cancer Res. 74:471. PubMed
23. Korrer MJ, et al. 2014. PLoS One. 9:91370. PubMed
24. Morshed M, et al. 2014. J Immunol. 192:5314. PubMed
25. Collins C, et al. 2014. PNAS. 111:9899. PubMed
26. Madireddi S, et al. 2014. J Exp Med. 211:1433. PubMed
27. Bianchi G, et al. 2014. Cell Death Dis. 5:1135. PubMed
28. Guo H, et al. 2014. J Leukoc Biol. 96:419. PubMed
29. Roderick JE, et al. 2014. PNAS. 111:14436. PubMed
30. Distel E, et al. 2014. Circ Res. 115:759. PubMed
31. Iwai H, et al. 2015. Tuberculosis. 95:246. PubMed
32. Charmsaz S, et al. 2015. PLoS One. 10:130692. PubMed
33. Whiteland J, et al. 1994 J Histochem Cytochem 43:3 (IHC-P)
34. Brown C, et al. 2003 J Immunology 171:2 (IHC-P)
35. Obregon-Henao A, et al. PLoS One 8:11 (IHC-P)

Product Citations

1. Ramirez-Moral I, et al. 2021. J Pathol. 253:374. PubMed
2. Cai S, et al. 2020. Sci Rep. 10:14249. PubMed
3. Malinczak CA, et al. 2021. J Immunol. 206:1315. PubMed
4. Li H, et al. 2022. Cancer Cell. 40:36. PubMed
5. Valet C, et al. 2022. J Clin Invest. 132: . PubMed
6. Li L, et al. 2023. Br J Pharmacol. 180:287. PubMed
7. Ruiz-Fernández de Córdoba B, et al. 2022. Cancer Discov. 12:1356. PubMed
8. Shirai T, et al. 2022. Cancer Sci. 113:3710. PubMed
9. Wolf Y, et al. 2017. J Exp Med. 214:905. PubMed
10. Weidner H, et al. 2020. JCI Insight. 5:00. PubMed
11. Li Y, et al. 2022. Int J Biol Sci. 18:3697. PubMed
12. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
13. Matsuno Y, et al. 2007. Am J Respir Crit Care Med. 176:1015. PubMed
14. Zou C, et al. 2020. Cell Rep. 33:108447. PubMed
15. Yang J, et al. 2022. Biosci Rep. :. PubMed
16. Bachran C, et al. 2017. Sci Rep.. 10.1038/s41598-017-17948-0. PubMed
17. Nederhoff MGJ, et al. 2019. Auton Neurosci. 221:102580. PubMed
18. Wang W, et al. 2018. Cancer Cell. 34:757. PubMed
19. Arnold IC, et al. 2018. J Exp Med. 215:2055. PubMed
20. Nguyen N, et al. 2022. iScience. 25:103679. PubMed
21. Zalacain M, et al. 2021. Mol Ther Oncolytics. 20:23. PubMed
22. Hameed AM, et al. 2020. Sci Rep. 5.229166667. PubMed
23. Cao Q, et al. 2018. Am J Physiol Renal Physiol. 314:F561. PubMed
24. Periasamy S, et al. 2017. Nat Commun. 8:15564. PubMed
25. Bernal S, et al. 2020. British Journal of Pharmacology. 178(3):564-581. PubMed
26. Lopez-Sanz L, et al. 2021. Clinical and Translational Medicine. 11(7):e463. PubMed
27. Joseph R, et al. 2021. Br J Cancer. 125:176. PubMed
28. Ronkina N, et al. 2019. J Immunol. 203:2291. PubMed
29. Dave K et al. 2017. eLife. 6 pii: e23382. PubMed
30. Magod P, et al. 2021. Cell Reports. 36(5):109480. PubMed
31. Peng V, et al. 2020. J Biol Chem. 295:14866. PubMed
32. Yang M, et al. 2020. Oncoimmunology. 9:1708064. PubMed
33. Liu Y, et al. 2022. Nat Commun. 13:2665. PubMed
34. Pérez-Hernández M, et al. 2021. Front Physiol. 11:623190. PubMed
35. Gautam J, et al. 2020. J Neuroinflammation. 17:103. PubMed
36. McCormick B, et al. 2019. J Immunol. 203:1579. PubMed
37. Suzuki Y, et al. 2021. FEBS Open Bio. 11:2619. PubMed
38. Wang H, et al. 2021. Nat Commun. 12:4826. PubMed
39. Hawila E, et al. 2017. Cell Rep.. 10.1016/j.celrep.2017.10.104. PubMed
40. Chen S, et al. 2018. Immunohorizons. 0.345138889. PubMed
41. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
42. Sun Y, et al. 2022. Nat Commun. 13:3916. PubMed
43. Yang SH, et al. 2017. Front Immunol. 8:1192. PubMed
44. Zhao L, et al. 2018. Nat Med. 24:1536. PubMed
45. Chen X et al. 2017. Cell stem cell. 21(6):747-760 . PubMed
46. Mori H, et al. 2015. Toxicol Pathol. 43: 883-889. PubMed
47. Telford W, et al. 2017. Cytometry A. 91:314. PubMed
48. Mainini F, et al. 2018. Nucleic Acid Ther. 28:225. PubMed
49. Hu G, et al. 2021. Nat Commun. 12:773. PubMed
50. Enders M, et al. 2020. J Immunol. 204:87. PubMed
51. Arnold S, et al. 2008. Exp Biol Med. 233:860. PubMed
52. Umemoto T, et al. 2017. EMBO J. 36:2390. PubMed
53. Tsubaki T, et al. 2018. Oncotarget. 9:11209. PubMed
54. Wicki S, et al. 2018. Int J Mol Sci. 1.266666667. PubMed
55. Piao Y, et al. 2012. Neuro Oncology. 14:1379. PubMed
56. Artz A, Butz S, Vestweber D 2016. Am J Physiol Renal Physiol. 311: F176 - F181. PubMed
57. Schuler CF, et al. 2020. Allergy. 75:2279. PubMed
58. Godoy-Calderón MJ, et al. 2018. Oncotarget. 8:11370. PubMed
59. Shevchenko MA, et al. 2018. J Immunol Res. 8:53. PubMed
60. Wang SS, et al. 2021. Cell Chemical Biology. 28(5):699-710.e5. PubMed
61. Wu Y, et al. 2020. Biol Reprod. 1213:102. PubMed
62. Tsukui H, et al. 2020. BMC Cancer. 20:411. PubMed
63. Zhang P, et al. 2022. Nat Commun. 13:1588. PubMed
64. Parigi SM, et al. 2018. Sci Rep. 0.440277778. PubMed
65. Ford J, et al. 2019. Front Immunol. 2.502083333. PubMed
66. Nguyen CH, et al. 2020. Biomedicines. 8:. PubMed
67. Bogorodskiy AO, et al. 2020. Front Immunol. 11:298. PubMed
68. Ritchie N, Ijaz U, and Evans T. 2017. BMC Genomics.. 10.1186/s12864-017-4215-3. PubMed
69. Ren AQ, et al. 2021. Front Pharmacol. 12:693298. PubMed
70. Ruiz-Fernandez de Cordoba B, et al. 2022. Cancer Discov. . PubMed
71. Scortegagna M, et al. 2020. Nat Commun. 11:99. PubMed
72. Akiel M, et al. 2017. Cancer Res. 77:4014. PubMed
73. Link CWM, et al. 2020. Front Immunol. 11:596772. PubMed
74. Lin Z, et al. 2021. Stem Cells. 39:240. PubMed
75. Mohrin M, et al. 2021. Aging Cell. 20:e13313. PubMed
76. Cané S, et al. 2021. J Immunother Cancer. 9:. PubMed
77. Jin H, et al. 2021. Int J Mol Sci. 22:. PubMed
78. Hwang BJ, et al. 2019. Oncogene. 38:7491. PubMed
79. Lee YJ, et al. 2018. Front Microbiol. 9:83. PubMed
80. Satoh–Takayama N, et al. 2020. Immunity. 52(4):635-649. PubMed
81. Heib T, et al. 2021. Cell Reports. 35(6):109102. PubMed
82. Diao J, et al. 2018. J Immunol. 201:1306. PubMed
83. Pushalkar S, et al. 2018. Cancer Discov. 0.613194444. PubMed
84. Winter C, et al. 2018. Cell Metab. 28:175. PubMed
85. Song M, et al. 2020. Nat Commun. 11:6298. PubMed
86. Dubik M, et al. 2021. Front Neurosci. 15:682451. PubMed
87. Rios–Doria J, et al. 2017. Cancer Res. 77:2686. PubMed
88. Zhang J, et al. 2019. Onco Targets Ther. 12:4985. PubMed
89. Alrefai H, et al. 2016. Nat Commun. 7:11724. PubMed
90. Shao Y, et al. 2017. Onco Targets Ther. 10:2675. PubMed
91. He X, et al. 2017. Cancer Biol Ther. 0.815277778. PubMed
92. Sparber F et al. 2019. British journal of pharmacology. 176(11):1728-1744 . PubMed

RRID

AB_313366 (BioLegend Cat. No. 108401)
AB_313366 (BioLegend Cat. No. 108402)

Antigen Details

Structure

21-25 kD

Distribution

Granulocytes, monocytes

Cell Type

Granulocytes, Monocytes, Neutrophils

Biology Area

Immunology, Innate Immunity

Antigen References

1. Fleming TJ, et al. 1993. J. Immunol. 151:2399.
2. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819.
3. Goni O, et al. 2002. Int. Immunol. 14:1125.

Gene ID

17067 View all products for this Gene ID 546644 View all products for this Gene ID

UniProt

View information about Ly-6G Ly-6C on UniProt.org

Documentation

• Technical Data Sheet (pdf)
• Certificate of Analysis
• Material Safety Data Sheet

Reviews

Related Protocols

• Cell Surface Flow Cytometry Staining Protocol

Related Pages & Pathways

Related FAQs

Other Formats

Certificate of Analysis